Evidence map›Paper›PMID 41699549›Full record

ArticleBMC cancer2026

Multi-omics SMR and experimental supportive analyses decipher causal drivers hepatocellular carcinoma.

Zhiya Yang, Tingyang Li, Jiayun Shen, Yao Huang, Chao Lei, Jiarui Yu, Zhaochen Ma, Ming Zhang, Ying Li

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiya Yang *Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China.ORCID http://orcid.org/0009-0000-4436-5464
Tingyang Li *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Jiayun Shen *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Yao HuangDepartment of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.ORCID http://orcid.org/0000-0002-5516-8842
Chao LeiGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Jiarui YuWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China.
Zhaochen MaInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Ming ZhangWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China. zyyzhangming@163.com.
Ying LiExperimental Research Center, China Academy of Chinese Medical Sciences, 100700, Beijing, China. liying1251@163.com.

Funding

China Academy of Chinese Medical Sciences Science and Technology Innovation Project ZN2023A02the Fundamental Research Funds for the Central Public Welfare Research Institutes No.JJPY2023005
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a highly prevalent and fatal digestive system malignancy, challenging to treat due to its latent onset and non-specific symptoms in advanced stages. Somatic mutations play a crucial role in hepatocarcinogenesis, with nearly half of HCC patients carrying oncogenic driver mutations such as TP53, CTNNB1, or TERT. In parallel, germline susceptibility variants identified by genome-wide association studies (GWAS) — including loci near TERT, MBOAT7, TM6SF2, and PNPLA3 — reveal inherited predisposition that shapes the molecular landscape for HCC development. Despite recent therapeutic advancements, long-term survival remains suboptimal, necessitating a deeper understanding of its pathogenesis and the identification of precise molecular targets. Traditional genomic studies, such as genome-wide association studies (GWAS), have successfully identified associated variants; however, due to their statistical design, they do not provide direct causal inference, functional supportive analyses, or comprehensive insight into multi-level molecular regulation and tumor microenvironment heterogeneity, serving instead as a critical starting point for subsequent functional and integrative analyses.

methodsTo address these gaps, this study employed an integrated multi-omics approach combining HCC GWAS summary data (FinnGen) with expression (eQTL from GTEx V8), methylation (mQTL), and protein (pQTL from ARIC, UKBPPP, DECODE) quantitative trait loci data. We utilized Summary-data-based Mendelian Randomization (SMR) to infer causal associations between molecular traits and HCC risk, prioritizing candidates with higher clinical translation potential. To refine SMR-based prioritization of candidate genes, bulk transcriptome sequencing and ELISA-based quantification were performed as complementary analyses on peripheral blood samples from 10 HCC patients and 10 healthy controls. Following SMR-based gene prioritization, bulk transcriptome and spatial transcriptomic analyses were first used to refine candidate selection and guide subsequent quantification, thereby avoiding unnecessary assays and optimizing the use of clinical samples and research resources. These analyses aimed to assess whether expression changes were directionally consistent with eQTL and pQTL effects, providing supportive—rather than confirmatory—evidence for the inferred genetic associations. Spatial transcriptomics was applied to HCC tissue sections to map region-specific expression patterns of candidate genes. Finally, publicly available single-cell RNA sequencing (scRNA-seq) data was analyzed to resolve cell composition changes, cell-type-specific expression, and intercellular communication networks within the HCC tumor microenvironment.

resultsMulti-omics SMR analysis identified numerous loci causally associated with HCC risk, with eQTL SMR revealing enrichment in critical cancer pathways (“Signal transduction,” “Cancer: overview,” “Immune system”). A robust and replicated causal signal for proteins was found on chromosome 19 across three independent pQTL cohorts, with a secondary signal on chromosome 2. The intersection of mQTL, eQTL, and pQTL SMR analyses yielded a core set of 16 candidate genes. Peripheral blood transcriptome profiling showed a clear separation between HCC and controls, with 13 of these 16 genes (e.g., LY9, ST6GAL1, SHMT1) significantly differentially expressed. ELISA validated elevated protein levels of ST6GAL1, PSMB1, LY9, and JUND, and decreased SOD4 in HCC patients. Spatial transcriptomics revealed significant intra-tumoral heterogeneity and distinct, localized expression patterns for genes like ST6GAL1, LGALS1, and JUND. Single-cell RNA sequencing unveiled shifts in cell type composition (e.g., increased Cytotoxic CD4 + T cells and MDSCs, decreased hepatocytes in tumors), cell-type specific expression of candidate genes, and complex intercellular communication networks.

conclusionBy integrating germline (GWAS-based) and somatic evidence, this study provides a comprehensive view of HCC pathogenesis. This integrated strategy successfully identified a core set of genes and proteins with potential causal links to HCC, elucidating their functional convergence in cancer biology. These findings offer novel molecular insights and candidate targets for precise diagnosis, prognostic assessment, and targeted therapy of HCC, laying a solid foundation for future translational research.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMultiomicsPolymorphism, Single NucleotideQuantitative Trait Loci

Identifiers

PMID41699549
PMCPMC13101365

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.